Evidence map›Paper›PMID 40800283›Full record

ArticleImaging neuroscience (Cambridge, Mass.)2024

Reduced expression of fMRI subsequent memory effects with increasing severity across the Alzheimer's disease risk spectrum.

Joram Soch, Anni Richter, Jasmin M Kizilirmak, Hartmut Schütze, Slawek Altenstein, Peter Dechent, Klaus Fliessbach, Wenzel Glanz, Ana Lucia Herrera, Stefan Hetzer and 22 more

Abstract read
In one paragraph

Article in Imaging neuroscience (Cambridge, Mass.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Joram SochGerman Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
Anni RichterLeibniz Institute for Neurobiology (LIN), Magdeburg, Germany.
Jasmin M KizilirmakGerman Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
Hartmut SchützeGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Slawek AltensteinGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Peter DechentMR-Research in Neurosciences, Department of Cognitive Neurology, Georg August University Göttingen, Göttingen, Germany.
Klaus FliessbachGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Bonn, Germany.
Wenzel GlanzGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Ana Lucia HerreraDepartment of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Stefan HetzerBerlin Center for Advanced Neuroimaging, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Enise I IncesoyGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Ingo KilimannGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Okka KimmichGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Bonn, Germany.
Dominik LammerdingDepartment of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Christoph LaskeGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Andrea LohseDepartment of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Falk LüsebrinkGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Matthias H MunkGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Oliver PetersGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Lukas PreisDepartment of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Josef PrillerGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Ayda RostamzadehDepartment of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany.
Nina Roy-KluthGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Bonn, Germany.
Klaus SchefflerDepartment for Biomedical Magnetic Resonance, University of Tübingen, Tübingen, Germany.
Anja SchneiderGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Bonn, Germany.
Annika SpottkeGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Bonn, Germany.
Eike Jakob SpruthGerman Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.
Stefan TeipelGerman Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.
Jens WiltfangGerman Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
Frank JessenGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Bonn, Germany.
Emrah DüzelGerman Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany.
Björn H SchottGerman Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In functional magnetic resonance imaging (fMRI) studies, episodic memory is commonly investigated with the subsequent memory paradigm in which brain activity is recorded during encoding and analyzed as a function of subsequent remembering and forgetting. Impaired episodic memory is common in individuals with or at risk for Alzheimer's disease (AD), but only few studies have reported subsequent memory effects in AD or its risk states like mild cognitive impairment (MCI). One reason for this might be that subsequent memory responses may be blunted in AD or MCI and thus less likely to manifest in fMRI signal differences. Here, we used Bayesian model selection of single-subject fMRI general linear models (GLMs) for a visual novelty and memory encoding experiment to compare the model performance of categorical and parametric subsequent memory models as well as memory-invariant models in a clinical cohort (N = 468) comprising healthy controls (HC) as well as individuals with subjective cognitive decline (SCD), MCI, and AD, plus healthy relatives of AD patients (AD-rel). We could replicate the previously reported superiority of parametric subsequent memory models over categorical models (Soch, Richter, Schütze, Kizilirmak, Assmann, Knopf, et al., 2021) in the HC and also in the SCD and AD-rel groups. However, memory-invariant models outperformed any model assuming subsequent memory effects in the MCI and AD groups. In the AD group, we additionally found substantially lower model preference for models assuming novelty compared to models not differentiating between novel and familiar stimuli. Our results suggest that voxel-wise memory-related fMRI activity patterns in AD and also MCI should be interpreted with caution and point to the need for additional or alternative approaches to investigate memory function.

Indexed as

Alzheimer’s diseaseBayesian model selectionepisodic memoryfunctional MRImild cognitive impairmentsubjective cognitive decline

Identifiers

PMID40800283
PMCPMC12290606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.